Skip to Content
Redy Biosciences
Home
Services
Plasmid DNA Preparation
CAR-T/CAR-NK Development
In Vivo CAR-T Development
Protein Expression Services
Cell Line Engineering
Genome Editing Verification
Products
Primary Cells
Cell Lines
Biosimilar Antibodies
About
Contact
Login Account
0
0
Redy Biosciences
Home
Services
Plasmid DNA Preparation
CAR-T/CAR-NK Development
In Vivo CAR-T Development
Protein Expression Services
Cell Line Engineering
Genome Editing Verification
Products
Primary Cells
Cell Lines
Biosimilar Antibodies
About
Contact
Login Account
0
0
Home
Folder: Services
Back
Plasmid DNA Preparation
CAR-T/CAR-NK Development
In Vivo CAR-T Development
Protein Expression Services
Cell Line Engineering
Genome Editing Verification
Folder: Products
Back
Primary Cells
Cell Lines
Biosimilar Antibodies
About
Contact
Login Account
Biosimilar Antibodies Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade

Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade

$150.00

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.

Specifications

Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894735

Molecular Weight: 150 kDa

Quantity:
Add To Cart

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.

Specifications

Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894735

Molecular Weight: 150 kDa

Amount: 100ug

Product Details

This non-therapeutic biosimilar antibody incorporates the same variable regions as the therapeutic antibody Tocilizumab, making it ideal for research use. It specifically binds to the human interleukin-6 receptor (IL-6R), also known as CD126—an 80 kDa type I cytokine receptor and member of the immunoglobulin superfamily. IL-6R is expressed on activated T and B lymphocytes, monocytes, hepatocytes, and plasma cells. The IL-6R α-chain binds IL-6 but requires dimerization with the signal-transducing subunit gp130 to initiate downstream signaling. This IL-6R–IL-6–gp130 complex regulates antigen-specific immune responses, drives inflammation, supports neuronal development, and plays a central role in the acute phase reaction. Tocilizumab binds both the membrane-bound and soluble forms of IL-6R, preventing IL-6 from engaging its receptor and thereby blocking signal transduction.

Specifications

Product name: Anti-human IL-6R (Tocilizumab Biosimilar) Research Grade

Species: Human

Storage condition: 4°C for short term; -20°C for long term

Note: For research use only. Not suitable for human use

Isotype: IgG1

Clonality: Monoclonal Antibody

Purity: >95% Determined by SDS-PAGE

Sterility: 0.2 µm filtration

Purification: Protein A

RRID: AB_2894735

Molecular Weight: 150 kDa

Redy Biosciences/RedyBio is a contract research organization (CRO) established by a team of seasons scientists, quality professionals, and biotechnology service experts.

Sign up with your email address to receive news and updates.

Your email is successfully captured. Thank you!

Links

Home

Services

Products

Contact us

About

Contact Us

Email:
info@redybio.com

Phone:
(858) 876-8688

Location:
6331 Nancy Ridge Dr. Suite A
San Diego, CA 92121